Navigation Links
Memory Pharmaceuticals Announces Six Abstracts Accepted for Presentation at Society for Neuroscience Meeting

MONTVALE, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that six abstracts related to its clinical and preclinical programs have been accepted for poster presentations at the 38th Annual Meeting of the Society for Neuroscience in Washington, D.C. from November 15-19, 2008. The abstracts include additional preclinical data for R3487/MEM 3454, the Company's lead nicotinic alpha-7 receptor agonist currently in Phase 2 development for both Alzheimer's disease and cognitive impairment associated the schizophrenia (CIAS), new preclinical data for the Company's lead 5-HT(6) receptor antagonist, MEM 68626, and data from its collaboration with Amgen focused on the development of PDE10 inhibitors.

"We continue to advance the development of novel therapies for the treatment of cognitive disorders and look forward to reporting on the new data emerging from our key programs," stated David A. Lowe, Ph.D., Chief Scientific Officer of Memory Pharmaceuticals. "We and our partner Roche are evaluating R3487/MEM 3454 as a treatment for both Alzheimer's disease and CIAS, and the preclinical data for R3487/MEM 3454 adds to the growing body of evidence suggesting the compound enhances cognition. In addition, MEM 68626 continues to demonstrate efficacy in multiple models of memory, including new findings of enhanced performance in a spatial working memory task. Furthermore, we continue to progress our program focused on advancing PDE10 inhibitors for potential clinical development."

The following abstracts from Company scientists and collaborators were accepted for poster presentations at the meeting:

-- "The alpha-7 receptor partial agonist MEM 3454 increases dopamine

and acetylcholine efflux in rat medial prefrontal cortex and

hippocampus, alone and augments the effect of atypical antipsychotic


Poster Session 874

Wednesday, November 19, 2008

1:00 p.m. - 5:00 p.m. EST

-- "Serotonin 5-HT(6) receptor antagonists modulate episodic, spatial

and working memory, highlighting a potential therapeutic role in

alleviating deficits associated with mild cognitive impairment and

Alzheimer's disease"

Poster Session 685

Tuesday, November 18, 2008

1:00 p.m. - 5:00 p.m. EST

-- "Identification and characterization of a novel small molecule

inhibitor for phosphodiesterase 10A as a potential PET-tracer using


Poster Session 885

Wednesday, November 19, 2008

1:00 p.m. - 5:00 p.m. EST

-- "Camk2(alpha) Heterozygous knock-out mice: a model of bipolar

disorder-related mania"

Poster Session 157

Sunday, November 16, 2008

8:00 a.m. - 12:00 p.m. EST

-- "Age and task dependent alterations in cognitive performance exist

in the rTg4510 mouse model of human tauopathy"

Poster Session 439

Monday, November 17, 2008

1:00 p.m. - 5:00 p.m. EST

-- "Behavioral characterization of rTg4510 tau transgenic mice"

Poster Session 439

Monday, November 17, 2008

1:00 p.m. - 5:00 p.m. EST

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Capital Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Memory Pharmaceuticals to Announce Third Quarter 2008 Results on Thursday, November 13, 2008
2. Leading London Neurosurgeon, Sim Farar, Partners with Los Angeles Fitness Guru to Help Baby Boomers Decrease Memory Loss
3. Alzheimers Foundation of America Offers Free Memory Screenings Nationwide
4. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
5. Help Employees Boost Memory, Lose Weight, Get Healthier & Increase Productivity
6. Circadian Rhythm Plays Role in Memory
7. Caribou Coffee Honors Memory of One of Its Own With Amys Blend
8. Hub of fear memory formation identified in brain cells
9. Whole brain radiation increases risk of learning and memory problems in cancer patients
10. New Brain Fitness Program to Fight Memory Loss
11. Exercise May Help Prevent Age-Related Memory Loss
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
Breaking Medicine Technology: